Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annexon, Inc. - common stock (NQ:ANNX)

5.425 +0.055 (+1.02%)
Streaming Delayed Price Updated: 2:28 PM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annexon, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Why Shares of Annexon Are Plummeting Thursday ↗
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock. 
Via The Motley Fool
News headline image
Why Annexon (ANNX) Stock Is Getting Hammered ↗
Annexon Inc (NASDAQ: ANNX) shares are trading lower by some 57.16% to $2.96 Thursday morning. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2023 ↗
 
Via Benzinga
News headline image
Dow Drops 100 Points; US GDP Tops Estimates ↗
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining over 1% on Thursday. Following the market opening Thursday, the Dow traded down 0.34% to 32,687.15 while the NASDAQ rose 1.36%... 
Via Benzinga
News headline image
Annexon's Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage Study ↗
 
Via Benzinga
News headline image
Analyst Ratings for Annexon ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Annexon ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about this morning! 
Via InvestorPlace
News headline image
Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon: Q3 Earnings Insights ↗
Annexon (NASDAQ:ANNX) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings Annexon beat estimated earnings by... 
Via Benzinga
News headline image
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022 ↗
  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗
Upgrades 
Via Benzinga
News headline image
The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Tesla, Twitter And 76 Biggest Movers From Friday ↗
Gainers Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board... 
Via Benzinga
News headline image
Tesla, WD-40 Company And 40 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Aditxt, Inc. (NASDAQ: ADTX) shares surged 75.7% to $0.2812 after the company's Adimune therapeutic program completed a toxicology study indicating a favorable safety profile of ADI-100. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.